AZD-4205

04/21

ALTERNATE NAMES: JAK1-IN-3; (2R)-N-[3-[2-[(3-methoxy-1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propanamide; 1-Piperazineacetamide, N-(3-(2-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-4-pyrimidinyl)-1H-indol-7-yl)-alpha,4-dimethyl-, (alphaR)-

CATALOG #:
B3124-1 1 mg
B3124-5 5 mg

STRUCTURE:



MOLECULAR FORMULA: $C_{25}H_{31}N_9O_2$

MOLECULAR WEIGHT: 489.6

CAS NUMBER: 2091134-68-6

APPEARANCE: Off-white crystalline powder

PURITY: ≥ 98%

SOLUBILITY: ~50 mg/ml in DMSO

DESCRIPTION: AZD-4205 is a highly selective Janus Kinase 1 (JAK1) inhibitor with an IC_{50} of 0.07 μM. It shows antitumor activity in combination with the EGFR inhibitor, osimertinib, in a preclinical non-small-cell lung cancer xenograft NCI-H1975 model. It targets cancer stem cell associated signalling pathway and microenvironment and is being evaluated in phase II clinical trials to treat advanced non-small-cell lung cancer.

STORAGE TEMPERATURE: -20 ºC. Protect from air. Store under desiccating conditions.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCES:

1. Yang, L., Shi, P. Zhao, G. et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 5(1):8 (2020).
2. Su, Q., Banks, E., Bebernitz, G. et al. Discovery of (2 R)- N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1 H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor. J Med Chem 63(9):4517-4527 (2020).

RELATED PRODUCTS:

Ruxolitinib phosphate (Cat. No. B2631)
EZSolution™ABT-494 (Upadacitinib) (Cat. No. B2486)
ABT-494 (Cat. No. B1947)
Peficitinib (Cat. No. B2474)
AZD1480 (Cat. No. 2315)

DISCLAIMER: ***FOR RESEARCH USE ONLY! Not to be used on humans.***